A drug combination extends survival in refractory lung cancer patients
Scientists have identified a drug combination, when used in advanced lung cancer patients, shows a survival advantage in patients who no longer respond to existing therapies. They found that bexarotene and erlotinib can each ...
Jun 2, 2011
0
0